Delivery Order SPE2DB25D3402-SPE2DB25FUGFV
- Not listed
- The Defense Logistics Agency awarded a $37,798.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Lotrel 10-20 mg capsules (100-count units) on August 21, 2025, with an ultimate completion date of August 22, 2025. This non-set-aside contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a competitive, firm fixed-price delivery order to AmerisourceBergen Drug Corp for $1,398.98 on February 3, 2026, for the supply of Lotrel 5-10 mg capsules (100-count units). This award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s substantial Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.9 million through December 31, 2031. The delivery order is scheduled for ultimate completion on...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide LOTREL 10-20 mg capsules. The $3,721.09 contract has a period of performance through March 18, 2024. AmerisourceBergen Drug Corp, located in Conshohocken, Pennsylvania, is the prime contractor on this delivery order. AmerisourceBergen Drug Corp also holds a larger indefinite delivery contract...
- The Defense Logistics Agency awarded a $2,412 delivery order to Amerisourcebergen Drug Corporation for the supply of 100 capsules of Lotrel 10-20 mg. The order was placed under an indefinite-delivery/indefinite-quantity contract vehicle and will be fulfilled by Amerisourcebergen from its facility in Conshohocken, Pennsylvania by August 28, 2023. Lotrel is a combination medication used to treat hypertension that contains benazepril hydrochloride and amlodipine besylate. The delivery order was...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of $81,406.88 worth of LOTREL 10-20 MG CAPSULE 100S. This delivery order falls under an indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Lotrel 10-20 mg capsules. The $31,616.33 firm fixed price contract has an ultimate completion date of August 22, 2024. This order is part of a larger indefinite delivery contract between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999, for delivering a comprehensive range of medical commodities to support...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 100-count bottles of the medication Lotrel 10-20 mg capsules, with a ceiling value of $9,619.77 and a period of performance through June 11, 2025. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that AmerisourceBergen holds...
- This $42,684.16 firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4563133674 - LOTREL 10-20 MG CAPSULE 100S, with a performance period ending on December 19, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, a leading global pharmaceutical sourcing and distribution company. The contract is for the delivery of Lotrel 10-20 mg capsules to support military treatment programs and facilities. The total ceiling value of the contract is $21,888.81, with a performance period ending on June 9, 2022. This...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of LOTREL 10-20 mg capsules. The award, with a ceiling value of $10,628.38, has a period of performance through September 5, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999, to provide a wide range of medical commodities, including...
- SPE2DB25D3402Indefinite Delivery Contract
- SPE2DB25D3402-SPE2DB25FUGFVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,611.49 to AmerisourceBergen Drug Corp for the supply of Lotrel 10-20 mg capsules (100-count units) on June 16, 2025, with an ultimate completion date of June 17, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award to this established pharmaceutical distributor. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a maximum value of $999,999,999.00 and extends through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Lotrel, a combination antihypertensive medication, represents one of numerous therapeutic categories the company delivers through this flexible contract vehicle to meet federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 6/16/25 |